_does-treatment-with-everolimus-octreotide-lar-affect-5-hiaa-levels-in-patients-with-advanced-nets-preview-1.jpg "Does Treatment with Everolimus + Octreotide LAR Affect 5-HIAA Levels in Patients with Advanced NETs? from everolimus chemotherapy Video Screenshot Preview 1")
Gallery_does-treatment-with-everolimus-octreotide-lar-affect-5-hiaa-levels-in-patients-with-advanced-nets-preview-3.jpg "Does Treatment with Everolimus + Octreotide LAR Affect 5-HIAA Levels in Patients with Advanced NETs? from everolimus chemotherapy Video Screenshot Preview 3")
Gallery_does-treatment-with-everolimus-octreotide-lar-affect-5-hiaa-levels-in-patients-with-advanced-nets-preview-hqdefault.jpg "Does Treatment with Everolimus + Octreotide LAR Affect 5-HIAA Levels in Patients with Advanced NETs? from everolimus chemotherapy Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 8 minutes 51 seconds
👁 View: 516 times
Play Audio:👁 View: 516 times
Description:
Oncology.TV
Oncology.TV
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_winship-grand-rounds-august-4-2021-jonathan-strosberg-md.webp "Winship Cancer Institute of Emory University")
_managing-the-toxicity-of-everolimus-in-breast-cancer.webp "OncLiveTV")
_92.webp "A self-confessed \")
_updates-in-the-management-of-neuroendocrine-cancers.webp "HMP Education")
_recent-advances-in-advanced-breast-cancer.webp "Prof Stephen Johnston – Royal Marsden Hospital, UK; Adjunct Prof Johanna Mattson - Helsinki University Central Hospital, Finland; Prof Ahmad Awada, Jules Bordet Institute, Belgium; Prof Rob Coleman - Weston Park Hospital, UK:nnnThe BOLERO (Breast Cancer Trials of Oral Everolimus) clinical trial is a study which assessed the use of the mTOR inhibitor everolimus in combination with exemestane as way to overcome endocrine resistance in breast cancer patients. Early results of this trial have show")
_integration-of-radiotherapy-in-muscle-invasive-bladder-cancer.webp "UBC Urology Rounds")
_winship-grand-rounds-july-19-2017-mehmet-asim-bilen-md.webp "Winship Cancer Institute of Emory University")
_results-from-the-geparquinto-trial.webp "Dr Huober discusses findings from the GeparQuinto study at SABCS 2011. The oral signal transduction inhibitor, everolimus, binds selectively to mTOR, an intracellular protein kinase implicated in the control of cellular proliferation of activated T-lymphocytes and neoplastic cells. Data suggested that everolimus can enhance the clinical efficacy of endocrine treatment in the metastatic and neoadjuvant setting.nnThe GeparQuinto phase III study had 3 settings: HER2-positive: trastuzumab vs lapat")
_winship-grand-rounds-august-4-2021-jonathan-strosberg-md.jpg)
_managing-the-toxicity-of-everolimus-in-breast-cancer.jpg)
_92.jpg)
_updates-in-the-management-of-neuroendocrine-cancers.jpg)
_recent-advances-in-advanced-breast-cancer.jpg)
_integration-of-radiotherapy-in-muscle-invasive-bladder-cancer.jpg)
_winship-grand-rounds-july-19-2017-mehmet-asim-bilen-md.jpg)
_results-from-the-geparquinto-trial.jpg)
![[+]](/images/menu.gif){kind=small}